Login to Your Account

Roche, Isis Join 'Hunt' for Brain Cures in $392M Partnership

By Catherine Shaffer
Staff Writer

Tuesday, April 9, 2013
Isis Pharmaceuticals Inc. and Roche AG have partnered to develop therapies for Huntington's disease using Isis antisense oligonucleotide (ASO) technology. The two companies will also work together to increase brain penetration of ASOs. Roche will pay $30 million up front to Isis, with milestone payments up to $362 million, including $80 million in commercial milestones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription